Faron Pharmaceuticals Oy
F:4FR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
Faron Pharmaceuticals Oy (4FR) under the Base Case is 0.24 EUR per share.
Compared with the current market price of 0.33 EUR, the stock appears
Overvalued by 27% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Faron Pharmaceuticals Oy Does
Faron Pharmaceuticals is a drug development company focused on medicines that change how the immune system behaves in cancer and severe inflammation. Its main work is to discover and test new drug candidates, especially bexmarilimab, an immunotherapy aimed at helping the body’s own defenses attack tumors. The company is not a mass-market drug seller; it is a research-stage biotech trying to turn lab findings into approved medicines.
- Headquarters
- Finland FI
- Employees
- 33
- IPO date
- Nov 17, 2015
Balance Sheet
Continue 4FR Research
Decided on Faron Pharmaceuticals Oy? Get an email when 4FR reaches the price you’d buy at. Free with an account.
Other Faron Pharmaceuticals Oy listings
What is the Intrinsic Value of one 4FR stock?
The intrinsic value for
Faron Pharmaceuticals Oy (4FR) under the Base Case is 0.24 EUR.
Is 4FR stock undervalued or overvalued?
Compared with the current market price of 0.33 EUR, the stock appears Overvalued by 27% .